New drug combo trial offers hope for older myeloma patients
NCT ID NCT04656951
Summary
This study is testing a treatment plan for older adults newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It adds the drug daratumumab to a standard three-drug combination for initial treatment, then continues it as a long-term maintenance therapy. The goal is to see if this approach is safe, effective at controlling the cancer, and still works if the cancer returns.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Cologne
Cologne, 50937, Germany
Conditions
Explore the condition pages connected to this study.